Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Use of Tofacitinib As First or Second-Line Therapy is Associated with Better Outcomes in Patients with Ulcerative Colitis: Data from a Real-World Study.

Antonio Tursi,Giammarco Mocci,Linda Cingolani,Edoardo Savarino,Roberta Pica,Andrea Cocco,Maddalena Zippi,Daniele Napolitano,Elisa Schiavoni,Daniela Pugliese,Franco Scaldaferri,Francesco Costa,Manuela Marzo,Mariaelena Serio,Antonella Scarcelli,Laura Bolognini,Emanuele Bendia,Giovanni Maconi,Rosanna Cannatelli,Simona Piergallini,Giorgia Bodini,Francesco Calabrese,Antonio Ferronato,Giuseppe Pranzo,Walter Elisei,Rita Monterubbianesi,Roberto Faggiani,Stefano Rodino,Ladislava Sebkova,Laurino Grossi,Federica Gaiani,Gianluigi de Angelis,Roberto Lorenzetti,Leonardo Allegretta,Alessia Immacolata Cazzato,Stefano Scorza,Nicola Della Valle,Rodolfo Sacco,Giacomo Forti,Raffaele Colucci,Paolo Tonti,Viviana Neve,Giulia Rocco,Carlotta Sacchi,Costantino Zampaletta,Cristiano Pagnini,Maria Giovanna Graziani,Maria Carla Di Paolo,Francesca Maria Onidi,Paolo Usai Satta,Marcello Picchio,Alfredo Papa

EXPERT OPINION ON PHARMACOTHERAPY（2023）

Cited 4|Views45
Key words
Ulcerative colitis,tofacitinib,real life,remission,safety
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined